Only days after revealing an unsolicited buyout bid from Lundbeck, Avadel—which has already signed an agreement to sell itself to Alkermes—has officially determined that the Lundbeck offer is sweet | ...

The phase 2 Cadence trial met its primary endpoint, showing that Winrevair improved the ability of blood to transition through the lungs to the heart in patients with combined post- and precapillary ...

Following the FDA’s September announcement of a crackdown on direct-to | Monday, the FDA’s Office of Prescription Drug ...

Now, more than half a year later, the expansion plan for one of the company’s new facilities—a former magazine plant in ...

Having found swift success with its Jazz Pharmaceuticals and BeOne Medicines-licensed cancer med Ziihera, Zymeworks has ...

Amid uncertainty for its vaccine division, CSL is growing the footprint of its bread-and-butter plasma therapies business by ...

Cytokinetics is following in the footsteps of Bristol Myers Squibb as it prepares to try to wrest control of a heart disease ...

The clock is up on Biogen’s extra two years of a biosimilar-free U.S. market for its blockbuster multiple sclerosis (MS) med ...

Novo revealed Monday that the self-pay cost for the two lowest dosages of Wegovy and Ozempic will be $349 per month, down ...

Despite many overseas drugmakers gaining some tariff clarity when the U.S. | Thanks to a new accord with the United States, ...

Three years after striking up a Zymeworks licensing pact with an eye on challenging the status quo in HER2-positive cancers, ...

In the past, biosimilar makers have been able to invalidate some of those patents through a sped-up process called “inter ...